FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138176478> ?p ?o ?g. }

• W3138176478 abstract "Abstract Benign prostatic hyperplasia (BPH) is ostensibly linked to autoimmune (AI) diseases, but whether the prostate is a target of systemic inflammation associated with AI conditions is unknown. Prostatic inflammation is linked to fibrosis, hyperplasia, and reduced responses to BPH-related medical therapies. This study was conducted to determine if AI disease correlates with BPH diagnosis and whether systemic targeting of an inflammatory mediator limits prostatic inflammation and hyperplasia. Patient medical records (n=112,152) were evaluated to determine BPH prevalence among different AI diseases. Inflammatory cells from human BPH tissues were analyzed by single-cell (sc)RNA-seq and the tumor necrosis factor (TNF)α-antagonist etanercept was tested in two murine models of prostatic enlargement. BPH prevalence was significantly higher among patients with AI disease compared to unaffected individuals. However, AI patients treated with TNFα-antagonists had a significantly reduced incidence of BPH. Data from scRNA- seq identified macrophages as a dominant source of TNFα and in vitro assays confirmed that TNFα stimulates BPH-derived fibroblast proliferation. In the AI patient cohort and murine models, systemic treatment with TNFα-antagonists decreased prostatic epithelial proliferation, macrophage infiltration, and epithelial NFκB activation compared to control tissues. These studies are the first to show that patients with AI diseases have a heightened susceptibility to BPH and that the TNFα-signaling axis is important for BPH pathogenesis. Macrophage-secreted TNFα may mechanistically drive BPH via chronic activation of the signaling axis and NFκB. TNFα blockade appears to be a promising new pharmacological approach to target inflammation and suppress BPH. One sentence summary Patient data and mouse models suggest that repurposing tumor necrosis factor alpha blockade reduces inflammation-mediated prostatic hyperplasia." @default.
• W3138176478 created "2021-03-29" @default.
• W3138176478 creator A5005453423 @default.
• W3138176478 creator A5015182396 @default.
• W3138176478 creator A5025036328 @default.
• W3138176478 creator A5032402680 @default.
• W3138176478 creator A5033159834 @default.
• W3138176478 creator A5040429122 @default.
• W3138176478 creator A5045918267 @default.
• W3138176478 creator A5047975067 @default.
• W3138176478 creator A5051542084 @default.
• W3138176478 creator A5058760833 @default.
• W3138176478 creator A5059821768 @default.
• W3138176478 creator A5063172323 @default.
• W3138176478 creator A5064665738 @default.
• W3138176478 creator A5069281759 @default.
• W3138176478 creator A5070992384 @default.
• W3138176478 creator A5072158231 @default.
• W3138176478 creator A5077600805 @default.
• W3138176478 creator A5078945196 @default.
• W3138176478 creator A5085035367 @default.
• W3138176478 creator A5090330103 @default.
• W3138176478 date "2021-03-12" @default.
• W3138176478 modified "2023-10-14" @default.
• W3138176478 title "TNF Blockade Reduces Prostatic Hyperplasia and Inflammation while Limiting BPH Diagnosis in Patients with Autoimmune Disease" @default.
• W3138176478 cites W1904353895 @default.
• W3138176478 cites W1959696062 @default.
• W3138176478 cites W1975907226 @default.
• W3138176478 cites W1986878226 @default.
• W3138176478 cites W198934061 @default.
• W3138176478 cites W1997066664 @default.
• W3138176478 cites W2003877413 @default.
• W3138176478 cites W2005020704 @default.
• W3138176478 cites W2016300251 @default.
• W3138176478 cites W2052268441 @default.
• W3138176478 cites W2061780050 @default.
• W3138176478 cites W2064095927 @default.
• W3138176478 cites W2064819768 @default.
• W3138176478 cites W2065637056 @default.
• W3138176478 cites W2069089843 @default.
• W3138176478 cites W2079974518 @default.
• W3138176478 cites W2094098906 @default.
• W3138176478 cites W2098293371 @default.
• W3138176478 cites W2102212449 @default.
• W3138176478 cites W2114104545 @default.
• W3138176478 cites W2115868428 @default.
• W3138176478 cites W2117395680 @default.
• W3138176478 cites W2118852628 @default.
• W3138176478 cites W2121759271 @default.
• W3138176478 cites W2123082894 @default.
• W3138176478 cites W2130116522 @default.
• W3138176478 cites W2131681506 @default.
• W3138176478 cites W2135398777 @default.
• W3138176478 cites W2145025818 @default.
• W3138176478 cites W2162760365 @default.
• W3138176478 cites W2169456326 @default.
• W3138176478 cites W2194261584 @default.
• W3138176478 cites W2286681607 @default.
• W3138176478 cites W2397260499 @default.
• W3138176478 cites W2461118037 @default.
• W3138176478 cites W2524019073 @default.
• W3138176478 cites W2739492614 @default.
• W3138176478 cites W2742739430 @default.
• W3138176478 cites W2801720382 @default.
• W3138176478 cites W2807525197 @default.
• W3138176478 cites W2897722618 @default.
• W3138176478 cites W2897926103 @default.
• W3138176478 cites W2898103663 @default.
• W3138176478 cites W2909143167 @default.
• W3138176478 cites W2921491548 @default.
• W3138176478 cites W2936910275 @default.
• W3138176478 cites W2939603004 @default.
• W3138176478 cites W2949243209 @default.
• W3138176478 cites W2950114058 @default.
• W3138176478 cites W2952100718 @default.
• W3138176478 cites W2963622568 @default.
• W3138176478 cites W2970463661 @default.
• W3138176478 cites W2981011290 @default.
• W3138176478 cites W2981216777 @default.
• W3138176478 cites W2990494536 @default.
• W3138176478 cites W2993908729 @default.
• W3138176478 cites W2997280954 @default.
• W3138176478 cites W3019682838 @default.
• W3138176478 cites W3020600422 @default.
• W3138176478 cites W3034718926 @default.
• W3138176478 cites W3084157821 @default.
• W3138176478 cites W4246062846 @default.
• W3138176478 cites W4248550912 @default.
• W3138176478 cites W4252684946 @default.
• W3138176478 cites W903656694 @default.
• W3138176478 doi "https://doi.org/10.1101/2021.03.11.434972" @default.
• W3138176478 hasPublicationYear "2021" @default.
• W3138176478 type Work @default.
• W3138176478 sameAs 3138176478 @default.
• W3138176478 citedByCount "1" @default.
• W3138176478 countsByYear W31381764782023 @default.
• W3138176478 crossrefType "posted-content" @default.
• W3138176478 hasAuthorship W3138176478A5005453423 @default.
• W3138176478 hasAuthorship W3138176478A5015182396 @default.
• W3138176478 hasAuthorship W3138176478A5025036328 @default.

• next